Hydroxychloroquine is one of the most valuable long-term medicines in rheumatology, and for most people it is very safe. Its one serious long-term hazard is damage to the retina, the light-sensitive tissue at the back of the eye. This article explains three things: why current guidance caps the daily dose at 5 mg per kilogram of actual body weight, what baseline and annual eye testing with optical coherence tomography (OCT) and visual fields is designed to find, and why the risk of retinal damage stays low for the first several years but rises steadily afterwards. The aim is to help patients understand their own monitoring well enough to take an active part in it alongside their doctors.
A medicine with deep roots, and real benefits
Hydroxychloroquine descends from quinine, the bitter alkaloid in the bark of the South American cinchona tree, which was used against malaria for centuries before anyone understood how it worked. Chemists built chloroquine from that template in the 1930s, and hydroxychloroquine followed as a less toxic relative. It is approved for malaria, systemic and discoid lupus erythematosus, and rheumatoid arthritis. Doctors also prescribe it off-label for other conditions, such as Sjögren's disease, where the evidence is thinner.
In lupus, its value is well established. In a randomised withdrawal trial published in the New England Journal of Medicine in 1991, the Canadian Hydroxychloroquine Study Group found that patients switched to placebo were about two and a half times more likely to have a flare than those who stayed on the drug. Large observational cohorts have since linked continued use with fewer flares, less organ damage, and longer survival. That observational evidence is consistent but cannot fully exclude other explanations. Hydroxychloroquine is also generally regarded as compatible with pregnancy in women with lupus, where controlling the disease protects both mother and child. One open-label study in anti-Ro-positive mothers, the PATCH study led from New York University and published in Circulation in 2020, reported a recurrence rate of congenital heart block of 7.4%, against a historical rate near 18%. Using the drug for that purpose is off-label and the study had no randomised control group, but it shows how much this medicine can matter for the very young.
Because the benefits are real and often lifelong, the goal of eye screening is not to frighten people off the drug. It is to let them stay on it safely, and to catch any problem early enough that a well-informed decision can be made.
How hydroxychloroquine affects the retina
Hydroxychloroquine binds strongly to melanin, the pigment found in the retinal pigment epithelium. This is the layer of cells that supports and maintains the photoreceptors. The drug accumulates there over time. It also interferes with lysosomes, the internal recycling system these hard-working cells depend on. The result, after prolonged exposure, is gradual loss of photoreceptors in a ring around the centre of vision.
Several features make this toxicity important to understand:
- It is painless and silent early on. Patients typically notice nothing until damage is moderate. They may then have trouble reading because letters drop out of words.
- It is not reversible. Lost photoreceptors do not regenerate.
- It can progress after stopping. The drug leaves the body slowly, with an elimination half-life measured in weeks. Tissue stores persist for longer still. Damage that is already advanced when found may continue to worsen for some time.
- The classic "bull's-eye maculopathy" is a late sign. This ring of pigment change visible on ordinary eye examination means substantial damage has already occurred. Modern screening aims to detect change long before that point.
The pattern also varies by ancestry. Work by Ronald Melles and Michael Marmor, published in Ophthalmology in 2015, showed that many patients of Asian descent develop damage further from the centre, in a "pericentral" pattern. Testing focused only on the central macula can miss this pattern.
The 5 mg/kg actual body weight threshold
For years, dosing guidance was based on "ideal" body weight, with a ceiling of 6.5 mg/kg. That changed after a landmark study from Kaiser Permanente Northern California by Melles and Marmor, published in JAMA Ophthalmology in 2014. They examined 2,361 patients who had used hydroxychloroquine for at least five years, using sensitive modern tests. Retinal toxicity was found in 7.5% overall. Its strongest predictor was daily dose relative to actual body weight, which predicted risk better than ideal weight did.
The study's estimates for doses of 4 to 5 mg/kg of actual weight were reassuring. The risk of toxicity was under 1% in the first five years and under 2% up to ten years, but it rose to almost 20% after twenty years. Doses above 5 mg/kg carried substantially higher risk at every stage. The study also identified other major risk factors. Chronic kidney disease roughly doubled the risk. Tamoxifen, a breast cancer drug, raised it several-fold.
On the strength of these data, the American Academy of Ophthalmology's revised recommendations, published in Ophthalmology in 2016, advised a maximum daily dose of 5.0 mg/kg of real body weight. The Royal College of Ophthalmologists in the United Kingdom adopted similar guidance. Later Kaiser cohort work led by April Jorge and colleagues, following patients from the start of treatment, supported a dose–response relationship. Higher doses were associated with higher rates of new retinopathy, and even recommended doses were not risk-free over long periods.
In practice, the arithmetic matters most for smaller patients. The traditional fixed dose of 400 mg a day exceeds 5 mg/kg in anyone weighing less than 80 kg (about 176 lb). For a 60 kg (132 lb) woman, the ceiling is 300 mg a day. Because tablets usually come in 200 mg strengths, prescribers often reach a weekly total by alternating doses. At the other extreme, some clinicians are cautious about letting very heavy patients reach high absolute doses simply because of weight, because the drug does not distribute evenly into fat. This is an area of clinical judgement rather than settled data.
Baseline and annual testing: OCT and visual fields
The 2016 recommendations set out a straightforward schedule:
- Baseline examination within the first year of starting the drug. This looks for pre-existing macular disease that could confuse later testing or make the drug unwise. Pre-existing retinal disease is itself considered a risk factor.
- Annual screening beginning after five years for patients on an appropriate dose without major risk factors.
- Annual screening from the start, or soon after, for those with risk factors such as kidney disease, tamoxifen use, or doses above the recommended ceiling.
Two primary tests are recommended, ideally together:
- Spectral-domain OCT uses light to produce a cross-sectional image of the retina, layer by layer, in seconds and without contact. Early toxicity appears as thinning of the outer retina and disruption of the photoreceptor layers in a ring around the fovea. In more advanced cases, the preserved centre surrounded by collapse gives the "flying saucer" appearance.
- Automated visual field testing maps sensitivity across the central vision as the patient responds to small lights. A 10-2 pattern is standard. Wider 24-2 or 30-2 patterns are advised for Asian patients to capture pericentral damage.
Each test covers the other's weaknesses. OCT is objective but can miss very subtle early change. Visual fields can detect early functional loss but depend on attention and can give false alarms. Fundus autofluorescence imaging and multifocal electroretinography are useful objective tests to confirm a suspicious finding. Older methods such as the Amsler grid, colour vision testing and simple fundus photography are no longer considered adequate for screening because they detect damage too late.
Why the risk climbs after five years
The low early risk and steep later rise follow from how the toxicity develops. Damage relates to cumulative exposure, the total amount of drug taken over years. Because the drug binds to melanin and leaves tissue slowly, it builds up in the pigment epithelium long after blood levels stabilise. Retinal cells can tolerate a certain burden before function fails. Below that point, little is detectable. Beyond it, losses accumulate.
Life itself adds to the risk. Kidney function tends to decline with age, and the kidneys clear a large share of hydroxychloroquine, so the same tablet produces higher drug levels over time. New medicines such as tamoxifen may be added. The retina also loses some of its reserve with age. This is why the five-year mark is a sensible point to begin annual checks for low-risk patients. It is not a cliff edge but the point where the evidence shows screening starts to pay its way. It is also why doctors should recheck body weight and kidney function periodically and adjust the dose if needed.
If screening finds a problem
A confirmed finding of toxicity generally means stopping the drug. That decision is weighed carefully against the disease it treats, especially in lupus, where alternatives carry their own risks. Discovering damage early, when it is limited to subtle OCT or visual field change, usually means vision is preserved and progression is minimal. This is the whole purpose of screening. Equivocal results are often repeated or confirmed with additional tests before any change is made, since stopping an effective medicine unnecessarily also has costs.
Patients do well to keep track of their own dose in mg/kg and their screening dates. They should tell both their prescriber and their eye doctor about kidney problems or new medicines. They should also be clear about whether their eye specialist is using OCT and visual fields. Good stewardship of one's sight, and of the years of health this medicine can protect, is a shared task between an informed patient and a physician who knows them.
Key takeaway: Hydroxychloroquine's retinal risk is low at doses of 5 mg/kg of actual body weight or less for the first several years, then rises with cumulative use, so a baseline eye exam and annual OCT and visual field testing from year five (or sooner with risk factors) let patients keep its benefits while catching damage early.